 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Zactane, Equagesic |
| Other names | Zactane |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.000.917 |
| Chemical and physical data | |
| Formula | C16H23NO2 |
| Molar mass | 261.365 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Ethoheptazine[1] (trade nameZactane) is anopioidanalgesic from the phenazepane family. It was invented in the 1950s[2] and is a ring expanded analogue ofpethidine.[3]
Ethoheptazine produces similar effects to other opioids, includinganalgesia,sedation,dizziness, andnausea.[4] It was sold by itself as Zactane, and is still available as a combination product withacetylsalicylic acid andmeprobamate asEquagesic, which is used for the treatment of conditions where both pain and anxiety are present.[5] It was also investigated for use as an antitussive.[6]
It is no longer prescribed, as it is no longer FDA approved, and not available for United States' Pharmacy Processing. Revocation of FDA Approved Medications Status stems from a combination of efficacy vs. toxicity, and the more-varied and historically safer benzodiazepines class. Only reversal of the FDA's decision, allows removing the drug from the CSD. Ethoheptazine is not listed as a controlled substance under the Controlled Substances Act, 1970 in the United States.[7] The controlled status (Schedule IV) of Equagesic was due to themeprobamate content.[8][7] Regulation elsewhere varies.